ABSTRACT

BACKGROUND AND PURPOSE: Transverse sinus venous stent placement has been shown to lower intracranial pressure in patients with venogenic pseudotumor cerebri and to reverse, or at least stabilize, its symptoms and signs. There have been no studies comparing the cost of venous stenting with the time-honored treatment for pseudotumor cerebri—CSF shunting. The purpose of this study was to compare the cost of transverse sinus stenting versus CSF shunting for the treatment of pseudotumor cerebri.

MATERIALS AND METHODS: This work was a retrospective cost analysis of individual resource use in 86 adults who were stented for pseudotumor cerebri during a 12-year period compared with resource use in 110 children who were shunted for hydrocephalus during a 3-year period.

RESULTS: There was no significant difference between the cost of inserting an initial venous stent ($13,863 ± 4890) versus inserting an initial CSF shunt ($15,797 ± 5442) (P = .6337) or between inserting an additional venous stent ($9421 ± 69) versus revising a CSF shunt ($10,470 ± 1245) (P = .4996). There were far fewer additional venous stent insertions per patient than there were subsequent CSF shunt revisions; 87% of stents placed required just 1 stent procedure, whereas only 45% of shunts required 1 shunt procedure. The main cause of the cost difference was the need for repeated revisions of the shunts, especially when they became infected—24 instances of a total 143 shunt procedures (16.8%) at an average cost of $84,729, approximately 5 times the cost of an initial shunt insertion.

CONCLUSIONS: Venous stenting costs significantly less per 100 procedures than does CSF shunting, due largely to the high cost of treating shunt infections and the need for repeated shunt revisions.

ABBREVIATIONS: PTC = pseudotumor cerebri; TSS = transverse sinus stenting

Transverse sinus venous stent placement is an effective treatment for pseudotumor cerebri (PTC)1,2; however, its cost has not been assessed or compared with the cost of the traditional alternative—CSF shunting. The annual cost of treating PTC in the United States exceeds US $444 million, and the annual cost of all CSF shunts—not just for PTC—exceeds $1 billion.3,4 We wanted to estimate the cost of transverse sinus venous stenting and compare it with the cost of CSF shunting. Because pediatric hydrocephalus typically requires CSF shunt insertion, this pediatric group was the most suitable one available for cost comparison.

Since the advent of venous sinus stenting for PTC, no patient has undergone CSF shunting at our institution for PTC. We reviewed the cost per patient for stent-versus-shunt insertion and reviewed the cost in terms of failed procedures, infection, and the need for revision, representing the full cost of these procedures.

MATERIALS AND METHODS

We reviewed the costs of treatment of 86 adult patients who had transverse sinus stenting (TSS) for PTC at Royal Prince Alfred Hospital between 2001 and 2012 and of 110 pediatric patients who had CSF shunting for hydrocephalus at Westmead Children’s Hospital between 2007 and 2009. Each procedure was classified as “new” (first time) or as “subsequent,” and details of complications were identified.

For each patient, a total annual cost was estimated on the basis of the individual patient’s resource use for that year. The cost comparison was undertaken from the perspective of the Sydney hospitals that provided the treatment, focusing on detailed, direct medical costs. Ethics approval was not required by Royal Prince Alfred Hospital.
Alfred Hospital because TSS is offered as a treatment. Ethics approval was separately provided by the Children’s Hospital Westmead Human Research Ethics Committee. All costs have been adjusted to 2012 levels in Australian dollars (AUD). The Australian dollar at the time of writing was roughly equivalent to 0.94 US dollars.

**Transverse Sinus Venous Stenting**
The 86 patients with PTC underwent 99 procedures during the 12-year period, with follow-up from 6 months to 10 years, with a mean of 4 years. All details of resource usage were collated for each stage of diagnosis and treatment. For preadmission, the main costs comprised the following: 1) consultations with a neurologist, ophthalmologist, radiologist, and anesthetist; 2) MR imaging; 3) lumbar puncture; 4) diagnostic direct retrograde cerebral venography and manometry; and 5) dual antiplatelet medication for 1 week before stenting and platelet function studies. The main hospital treatment costs comprised the following: 1) therapeutic diagnostic direct retrograde cerebral venography; 2) general anesthesia; 3) the stent; 4) medication during the procedure, primarily heparin; and 5) postprocedure accommodation, usually 1 night in a high-dependency unit. One-third of patients stayed an additional night in a general hospital bed for further observation.

This information provided measurement of all resource use, length of stay, and revision rates. Valuation of resources was then incorporated by using published service schedules and unit costs, principally from the Australian Medical Benefits Scheme and published Diagnostic Related Groups; and specific costs, when necessary, were provided by the Royal Prince Alfred Radiology Department. The approach and costing sources used in this study are consistent with Australian government guidelines for preparing health economic analyses.6

**CSF Shunting**
The 110 patients had 143 procedures during the 3 years, for shunt insertion, shunt revision, and shunt infection, with no subsequent follow-up beyond the study period. Actual hospital costs were provided by the Children’s Hospital Westmead by using the Power Performance system. This is a clinical inpatient costing system linking resource cost inputs and allocation to each individual patient on the basis of actual use. Allocation algorithms are applied to relevant source feeds from each system, including imaging, pathology, pharmacy, operating theater, and physiotherapy. Resource use is captured by the time used, so costs reflect the duration of surgical procedures, the number of nurses, the duration of anesthesia, and so forth.

Following extraction of the detailed costing data from the Power Performance Manager, review of records was undertaken to classify each episode. This was to exclude non-hydrocephalus primary diagnoses and to categorize patients as having a new shunt or a shunt revision. Patients with CSF shunts were additionally classified if they developed infection, to assess separately the cost of treatment. Patients with hydrocephalus secondary to trauma, malignancy, or other complex conditions (except myelomeningocoele) were excluded. Figures from the Power Performance Manager were adjusted to the 2012 AUD by using the total health price index published by the Australian Institute of Health and Welfare 2012.7

**Statistics**
The mean costs of each group were analyzed by using the Student t test, and a χ² test was used for demographic independence with a P value < .05 considered statistically significant. Several 1-way sensitivity analyses were performed to establish whether the comparative results were sensitive to cost, infection, or revision rate variables. These included using costs, infection, and revision rates and the total number of revisions per patient from studies of equivalent adult shunt cohorts to validate comparable age-matched scenarios. Statistical analysis was undertaken by using STATA statistical software (Special Edition, Version 12.1 2011; StataCorp, College Station, Texas).

**RESULTS**

**Patient Groups**
The baseline demographic characteristics for transverse sinus stent and CSF shunt patients are presented in Table 1.

A χ² test of independence confirmed the difference between the 2 demographic groups (P < .001).

**Number of Procedures**
Most stented patients had just 1 stent at 1 procedure (Table 2); in contrast, many patients with CSF shunts needed further procedure revisions and treatment of infections (Table 3). The stented patient group, during the 12-year period, underwent 99 stent procedures, 78 of 86 patients receiving a single procedure (90.7%) and the remaining 8 having additional stents: 5 patients, just 1 more; 1 patient, 2 more; and 2 patients, 3 more.

In contrast, the CSF shunt group had 143 procedures, only 40 of which (28%) were first-stunt insertions (Table 3).

**Average Cost**
There was no significant difference between the average cost of an initial venous stenting ($13,863 ± 4890) and an initial CSF shunting ($15,797 ± 5442) (P = .6337); any difference is attributable to a few serious high-cost complications that

---

**Table 1: Baseline demographics of patients with transverse sinus stents and CSF shunts**

<table>
<thead>
<tr>
<th>Age and Sex</th>
<th>No. of Patients (%)</th>
<th>Transverse Sinus Stent (n = 86)</th>
<th>CSF Shunt (n = 110)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (yr)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>10 (11.6)</td>
<td>78 (70.9)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>76 (88.4)</td>
<td>32 (29.1)</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2: Venous stents: number of patients by initial and repeat procedures**

<table>
<thead>
<tr>
<th>No. of Stent Procedures per Patient</th>
<th>No. of Patients</th>
<th>Stent Procedures per Patient</th>
<th>No. of Stent Procedures</th>
<th>% Total Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>New stent procedure</td>
<td>78</td>
<td>1</td>
<td>78</td>
<td>90.7%</td>
</tr>
<tr>
<td>1 Subsequent procedure</td>
<td>5</td>
<td>2</td>
<td>10</td>
<td>5.8%</td>
</tr>
<tr>
<td>2 Subsequent procedures</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>1.2%</td>
</tr>
<tr>
<td>3 Subsequent procedures</td>
<td>2</td>
<td>4</td>
<td>8</td>
<td>2.3%</td>
</tr>
<tr>
<td>Total</td>
<td>86</td>
<td>99</td>
<td>100.0%</td>
<td></td>
</tr>
</tbody>
</table>
occurred during the initial shunting. The influence of these complication outliers on the mean is reflected in the even closer median for each initial procedure at $9374 for venous stenting and $9535 for CSF shunting. The CSF shunting average costs for first procedures and revisions excluded infection, which was classified separately to evaluate its cost implications. This infection component was combined with other classification group average figures in the cost per 100 cases presented below.

Similarly, there was no significant difference between the average cost of a subsequent venous stenting ($9421 ± 69) and of a CSF shunt revision ($10,470 ± 1245) (P = .4996), and there was no difference in the median cost, $9374 for venous stenting versus $9029 for CSF shunting.

With resource usage for venous stenting similar to that for CSF shunting, the average cost of each first and subsequent procedure was not significantly different. The lower average cost of subsequent compared with new procedures is largely due to high-cost complications occurring in only new stent procedures, as well as high-cost shunt complications being separately categorized as infection cases, so there were no high-cost outliers increasing the average revision cost. The average costs for CSF shunting reported here are in line with previous data.8,9

### Additional Stents versus Revised Shunts

The main cause of the cost difference between stenting and shunting is the need for subsequent procedures: 79/143 (55.2%) for shunting but only 13/99 (13.1%) for stenting. While the average cost per procedure is similar, the proportional cost in terms of the total number of subsequent procedures is higher for shunting.

### Infection

An important difference between shunts and stents is that shunts do not get infected. Infection necessitated 24 shunt revisions (16.8%), often incurring the additional cost of removing and eventually replacing the shunt and all the associated costs of medical treatment to eradicate the infection. This is reflected in the higher average cost of treating an infected shunt ($84,729 ± 59,939) rather than inserting a new shunt ($15,797 ± 17,015) or just revising a shunt ($10,470 ± 5557), as well as in the longer average length of stay of 44 days, compared with 9 days for an initial shunt and 6 days for a revised shunt. Therefore, shunt infections are a major cost component; although they represent only 16.8% of cases, they account for 58.2% of the total cost, $2 million for the 3-year shunt group. Similar rates of shunt infection from 7.2%–15% and comparable 5-fold average cost increases in hospital charges have already been reported.9,10 Previous research has also shown that patients with adult PTC shunts similarly experience complications in this range with a 9% shunt infection rate.11

### Cost per 100 Procedures

To allow for the different study and follow-up periods of the shunted and stented patients and for the presence of infection, the average costs per procedure, both new and subsequent, are calculated in terms of cost per 100 procedures (Table 4). These results reflect the high revision rate for CSF shunts, multiplied by the average procedure cost in each group, as well as the cost of managing infected CSF shunts.

In these terms, the cost per 100 cases is significantly higher for CSF shunting, almost double that for venous stenting (Fig 1). The reason for this is the higher proportion of CSF shunt revisions and the higher cost of shunt complications, not the average cost per procedure.

The cost per 100 cases, however, underestimates the true comparable long-term cost of ongoing revisions. Because the stented group continued for 12 years, it is reasonable to view the absolute number of additional stentings as representative; >90% of patients had just a single stenting, with a maximum 3 additional stentings in only 2 patients. The shunting study period by comparison, covering only 3 years, was sufficient to provide an estimate of the average cost per revision but cannot provide an adequate follow-up period to verify the total number of shunt revisions needed by each patient.

Thus, a literature review was undertaken to verify revision rates and, in particular, the total number of revisions per patient;
this indicated revision rates resulting from complications such as blockage and infection between 25% and 55%. The pattern of ongoing shunt complications has also been reported in adult PTC shunt groups, with similarly high revision rates of 51%—63%. Furthermore, some “shunt-intolerant” patients can require ≥10 ventriculoperitoneal shunt revisions and >30 lumboperitoneal shunt revisions. As for the infection and revision rates, previous research has also reported cases of ≥10 revisions per patient in adult PTC shunt groups. In contrast, the highest number of stent procedures recorded for 1 patient was 4.

**Total Cost per Patient**

These results provide the average cost per procedure and separately indicate the revision and infection rates, which in turn determine the total cost per patient for each group. There are many more high-cost shunt patients than stent patients (Fig 2). The relative difference is in higher cost shunt patients overall and, in particular, the scale of costs required to manage the top 2% of patients with severe complications. Stent and shunt patients in the lower 40% by cost have similar, single procedures with no infection. Above 40%, the shunt patient costs increase consistently to the highest cost, 4%, around $100,000, 3-fold the comparable highest cost of stent patients. While both groups include extreme outliers in the highest cost 2% of patients, the scale of the shunted patients continues to be at least 3-fold higher than the stented patients, again reflecting the higher rates of infection and ongoing shunt revisions. Length-of-stay figures are also presented for each percentile group.

**Complications**

Complications after stenting included headache, transient hearing loss, and allergic reactions to aspirin or clopidogrel and, in one case, an anaphylactic reaction to the anesthetic. Apart from these cases, there were 3 patients from the total of 86 in the transverse sinus stent group (3.5%) who had major neurologic complications during stenting, largely vein perforation causing subdural, subarachnoid, or intracerebral bleeding. All 3 patients made a full recovery; 2 needed an urgent craniotomy for evacuation of a hematoma.

From a resource use and cost perspective, the 3 severe-complication cases required extended inpatient stays and ongoing rehabilitation. From a cost perspective, these patients are extreme outliers with a total individual cost of $119,468, $135,440, and $143,272. In comparison, severe complications for the 3 highest cost shunt patients resulted in individual patient costs of $170,850, $411,619, and $641,824.

**Total Revisions per Patient**

To explore the potential cost implications of subsequent procedures, especially shunt revisions, a series of scenarios were developed on the basis of average costs from the 2 datasets supported by evidence from previous studies. These provided cross-validated estimates of the average cost of initial stenting or shunting, as well as of subsequent procedures, infection risk, and associated
average infection cost. These scenarios are consistent with studies of adult patients with PTC shunts, as referenced in previous sections, which have shown infection and revision rates and the total number of shunt revisions per patient to be similar to those of our pediatric study group.

These findings then support a series of scenarios based on the total number of additional procedures per patient as presented in Fig 3. The maximum number of subsequent stentings in the 12-year group was 3, and additional stenting beyond 5 have not been reported, so 5 is considered the maximum upper limit. In this context, the first scenario illustrates the relative comparison of 5 subsequent stentings and 5 subsequent shunt revisions, with the slightly higher total cost of shunting due to the additional cost of managing infections.

Additional scenarios were prepared to investigate a reduced infection rate for CSF shunting with use of antibiotic-impregnated shunts, which included infection rates below those reported in previous adult study groups.17

In the scenarios of 8 and then 10 revisions, shown only for shunts, the trend is further established. While 10 revisions are presented as an extreme scenario, there have been reports of adult patients with PTC needing even more, which extends the increasing cost trend for patients with higher revision shunts.14,18

Previous modeling suggests that the cost of shunting in pediatric hydrocephalus is more sensitive to the revision rate, particularly in the first year after shunting, than to the decreased infection rate or length of hospital stay.19 Also long-term investigations of shunted children have confirmed that 81% need at least 1 revision and often several, requiring repeated procedures and hospitalizations.13

The shunt infection column bars in Fig 3 report the shunt infection rate of the study group (16.8%), which is shown against 2 reduced-infection-rate sensitivity scenarios of 10% and 5%. These scenarios indicate that even with an infection rate of only 5%, a patient receiving 10 shunt revisions is estimated to cost $196,771, almost a 4-fold increase in the highest cost of inserting 5 additional stents. Despite reported examples of reduced shunt infection rates, rates of 10% still occur even with antibiotic-impregnated shunts.20 As described previously, adult patient groups with PTC shunts have been reported as having a similar 9% infection rate. Here, the estimated cost of $239,136 is close to 5-fold the highest cost for a stented patient. In all scenarios with $>5$ subsequent procedures, an increasing upward cost trend resulted for shunts, in line with the number of procedures, shown as the dotted triangle in Fig 3.

In summary, the average cost per 100 patients, the total cost per patient, and the skewed upside risk of additional costs through ongoing shunt revisions and infections show stenting costing less than shunting, while nonetheless providing patients with PTC with effective long-term treatment.

**DISCUSSION**

In the first part of this study, we calculated the average cost of venous stenting and CSF shunting and found no significant difference between the 2, either as initial or subsequent procedures. This finding reflects similar resource use, operating theater time, and medical-surgical team composition for each procedure and provides the underlying base-cost component to the calculation of total cost per patient. The main cause for the cost difference between stenting and shunting is, therefore, not the difference in average cost for each routine procedure but problems and complications with CSF shunting, leading to a high revision rate, up to 30% for ventriculoperitoneal shunts and 60% for lumbo-pertoneal shunts and an infection rate of 5%–15%. These cost drivers are consistent with similar shunt revision and infection rates previously reported in adult PTC study groups.21

It follows that ongoing additional stents and shunt revisions are simple multiples of the average cost; the key difference between stenting and shunting is that shunts not only need frequent revisions, they also can become infected and this outcome results in higher total costs. The analysis scenarios in this study have taken the conservative case of 10 revisions for shunts, though even
more can occur in both pediatric and adult PTC cases. There remains, therefore, an unbounded upside risk for a few shunt-intolerant patients, which will potentially add substantially to total cost per patient.

Venous stenting, by comparison, has been shown to require significantly fewer repeat procedures, with >90% of patients successsfully receiving just a single stent. Also, the need for additional venous stenting, while low, has been further lowered with time, due to a better understanding of the mechanism by which stents lower intracranial pressure and the availability of longer stents. We have proposed that stenting prevents compression of the transverse sinuses by intracranial hypertension itself, breaking a positive feedback cycle. A stent creates a rigid, noncollapsible transverse sinus, one no longer vulnerable to compression from intracranial hypertension so that CSF absorption is improved, lowering intracranial pressure. With time, longer stents have been inserted so that fewer extrinsic stenoses develop at the distal end of the stent, reducing the need for second or third stenting procedures. In some cases, the entire transverse sinus has been stented.

Given this significant difference in the repeat rates of the 2 procedures, the cost per 100 cases does not represent the total longer term cost per patient of ongoing revisions. Because the venous stent group was followed up to 12 years, it is reasonable to view the absolute number of repeat procedures as representative. During the 12 years of data, >90% of patients received only a single stent, with a maximum of 3 revisions in 2 cases. The shunt study period by comparison, covering 3 years, is sufficient to provide an estimate of average cost per revision but cannot provide an adequate follow-up period to verify the lifetime total number of shunt revisions per patient.

Revision rates resulting from shunt complications, such as blockage and infection, range from 25% to 50% or more, suggesting that the long-term costs of CSF shunting could be even higher than we found here.

In addition to high-cost cases of ongoing revisions, infection is also an important factor in the overall higher total cost per shunt patient. A few infected shunts result in a disproportionately high shunting cost increase, typically 4- to 5-fold higher than a noninfected case. In our shunt group, the 16.8% of infections accounted for 58.2% of total cost, over $2 million.

The rate and costs of infection are being reduced with the wider use of antimicrobial impregnated sutures, shunts, and catheters to below 5% in some cases, though this level of reduction would depend on using impregnated devices in all shunt procedures, and there is some reluctance to use them because of their increased cost.

Given the variation in shunt infection rates and potentially reduced rates resulting from the more widespread use of antibiotic-impregnated shunt components, our scenario analyses included reduced infection rates of 10% and 5%, to investigate the impact on total cost. The scenarios demonstrate that reduced rates of infection, while reducing the magnitude of the cost difference, nonetheless confirm the substantially lower cost of venous stenting in all cases. Because the infection component has been isolated and analyzed separately, even if infection rates were reduced to zero, venous stenting would still cost substantially less than CSF shunting.

The benefit of venous stenting in PTC is now clear, and a lower complication rate (9.3% of patients in our own study) compared with shunting has been reported in all studies. We have now shown that the cost of stenting is also significantly less than that of shunting. Finding a therapeutically effective and cost-effective treatment for PTC is of growing importance, given the increasing cost of PTC and the growing rates of obesity.

**Study Limitations**

Our study has 1 noteworthy limitation: Our CSF shunting group was composed of pediatric patients with hydrocephalus, and it is often suggested that the complications of shunting are more common in pediatric than in adult patients. The ideal comparison group would have been adult shunted patients with PTC. Unfortunately these data were not available because new adult patients at our institution, and in fact in our state, who have PTC with venous stenosis have been so rarely shunted since stenting became available. Therefore, we decided to choose as a comparison group to our stented patients a group of pediatric patients from a prospective registry of cases kept at the Westmead Children’s Hospital. To balance this limitation, we reviewed the literature on complications of shunting for adult PTC and verified that the key cost drivers of infection and revision rates and the total number of revisions per patient have been reported at levels similar to those in our pediatric hydrocephalus study group.

In this context, we are confident that our work is valid and adds significantly to the debate on the role of stenting versus shunting in the treatment of venogenic PTC.

The study is also limited by its retrospective nature, and ideally a prospective study comparing the cost of stenting versus shunting is needed in a group of adult patients with PTC.

**CONCLUSIONS**

In treating PTC, transverse sinus stenting costs less than CSF shunting in the long term, not because of the average cost of the procedure itself but as a result of a relatively lower revision rate, fewer total revisions per patient, and no infections to date.

**REFERENCES**

Australian Government, Department of Health and Aging, Canberra, Australia, December 2009


